Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - 17 Nov 2022 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role: 10%+ Owner
Signature: /s/ Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter McIsaac, Title: Authorized Person
Issuer symbol: ACRV
Transactions as of: 17 Nov 2022
Net transactions value: $0
Form type: 4
Filing time: 21 Nov 2022, 12:22:18 UTC
Previous filing: 09 Nov 2022
Next filing: 27 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRV	Common Stock	Conversion of derivative security		+888,130			888,130	17 Nov 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRV	Series B Preferred Stock	Conversion of derivative security	$0	-2,190,131	-100%	$0.000000^*	0	17 Nov 2022	Common Stock	888,130		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Wellington Biomedical Innovation Master Investors (Cayman) I L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date.